Low-molecular-weight cyclin E: the missing link between biology and clinical outcome
AUTOR(ES)
Akli, Said
FONTE
BioMed Central
RESUMO
Cyclin E, a key mediator of transition during the G1/S cellular division phase, is deregulated in a wide variety of human cancers. Our group recently reported that overexpression and generation of low-molecular-weight (LMW) isoforms of cyclin E were associated with poor clinical outcome among breast cancer patients. However, the link between LMW cyclin E biology in mediating a tumorigenic phenotype and clinical outcome is unknown. To address this gap in knowledge, we assessed the role of LMW isoforms in breast cancer cells; we found that these forms of cyclin E induced genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. These findings suggest that high levels of LMW isoforms of cyclin E not only can predict failure to endocrine therapy but also are true prognostic indicators because of their influence on cell proliferation and genetic instability.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=549170Documentos Relacionados
- LOW-MOLECULAR-WEIGHT RHEUMATOID FACTOR*
- Low-molecular-weight xylanase from Trichoderma viride.
- Low-Molecular-Weight Heparins in the Cardiac Catheterization Laboratory
- Evidence for a low-molecular-weight collagen precursor.
- Relation between Seroreactivity to Low-Molecular-Weight Helicobacter pylori-Specific Antigens and Disease Presentation